Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Journal of Oncology
J E BohonowychJennifer S Isaacs

Abstract

Tumor vascularization is an essential modulator of early tumor growth, progression, and therapeutic outcome. Although antiangiogenic treatments appear promising, intrinsic and acquired tumor resistance contributes to treatment failure. Clinical inhibition of the molecular chaperone heat shock protein 90 (Hsp90) provides an opportunity to target multiple aspects of this signaling resiliency, which may elicit more robust and enduring tumor repression relative to effects elicited by specifically targeted agents. This review highlights several primary effectors of angiogenesis modulated by Hsp90 and describes the clinical challenges posed by the redundant circuitry of these pathways. The four main topics addressed include (1) Hsp90-mediated regulation of HIF/VEGF signaling, (2) chaperone-dependent regulation of HIF-independent VEGF-mediated angiogenesis, (3) Hsp90-dependent targeting of key proangiogenic receptor tyrosine kinases and modulation of drug resistance, and (4) consideration of factors such as tumor microenvironment that pose several challenges for the clinical efficacy of anti-angiogenic therapy and Hsp90-targeted strategies.

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·J G SupkoL Malspeis
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·O IliopoulosM A Goldberg
May 15, 1998·Nature·G García-CardeñaW C Sessa
Feb 12, 1999·Molecular Genetics and Metabolism·H J OchelL Neckers
Jun 11, 1999·Japanese Journal of Pharmacology·A Nakamura, H Shiomi
Sep 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·S SatoT Tsuruo
May 10, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N ReinmuthL M Ellis
Sep 6, 2001·Intensive Care Medicine·A Hamad, N Sharma
Nov 14, 2001·Seminars in Oncology·R Kumar, R Yarmand-Bagheri
Feb 1, 2002·Nature Medicine·Wadih ArapRenata Pasqualini
Mar 1, 2002·Internal Medicine·Gregg L Semenza
Apr 3, 2002·Trends in Molecular Medicine·Len Neckers
Jun 8, 2002·The Journal of Biological Chemistry·Jennifer S IsaacsLeonard M Neckers
Aug 3, 2002·Environmental Microbiology·Sasha Shafikhani
Oct 16, 2002·Journal of Korean Medical Science·Yang-Sook ChunJong-Wan Park
Dec 10, 2002·The Journal of Biological Chemistry·Sylvie J LavictoireIan A J Lorimer
Dec 10, 2002·Human Molecular Genetics·Stefano CampanaroGerolamo Lanfranchi
Apr 5, 2003·Cancer Cell·Jennifer S IsaacsLen Neckers
May 3, 2003·Cancer Cell·Selma PennacchiettiPaolo M Comoglio
May 3, 2003·The Journal of Clinical Investigation·Gabriele BergersDouglas Hanahan
Oct 8, 2003·Current Cancer Drug Targets·Luke WhitesellRyan Falsey
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Dec 9, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Jian-xiong Chen, Barbara Meyrick
Dec 11, 2003·Atherosclerosis. Supplements·John P Cooke
Dec 12, 2003·Cancer Cell·Jason A HoffmanErkki Ruoslahti
May 11, 2004·Nature Biotechnology·Peter M Smith-JonesSteven M Larson

❮ Previous
Next ❯

Citations

Mar 31, 2012·Frontiers of Medicine·Bingxue ShangQuansheng Zhou
Aug 1, 2013·Pathology Oncology Research : POR·J M Patki, S S Pawar
Sep 29, 2011·ACS Chemical Biology·Veronica C ArdiShelli R McAlpine
Dec 14, 2011·Journal of Cancer Research and Clinical Oncology·Robert FarkasSzabolcs Bellyei
Nov 19, 2014·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Yizhe ChenDarin Y Furgeson
May 18, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hitomi KoizumiSeiji Yano
Aug 19, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yizhe ChenDarin Y Furgeson
Nov 22, 2014·Seminars in Ophthalmology·Eduardo Cárdenas-CantúJorge E Valdez-García
Feb 1, 2017·ChemMedChem·Yao WangShelli R McAlpine
Feb 18, 2012·Molecular & Cellular Proteomics : MCP·Zhixiang WuBernhard Kuster
Oct 25, 2011·Pharmaceuticals·Peter W Piper, Stefan H Millson
Oct 22, 2014·Chemical Communications : Chem Comm·Y Wang, S R McAlpine
Jul 22, 2014·Journal of Gynecologic Oncology·Ramez N Eskander, Krishnansu S Tewari
Nov 1, 2010·Expert Opinion on Drug Discovery·Nicholas C NicolaidesLuigi Grasso
Sep 20, 2012·The Journal of Biological Chemistry·Michael W HanceJennifer S Isaacs
Dec 11, 2013·Organic & Biomolecular Chemistry·Hendra WahyudiShelli R McAlpine
May 13, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ayelet HerzogMark Pines
Jan 1, 2014·ACS Medicinal Chemistry Letters·Seong Jong KimShelli R McAlpine
Jul 23, 2014·ACS Medicinal Chemistry Letters·Yen Chin KoayShelli R McAlpine

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotide
xenograft
dissection
phage display

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.